Clinical Trials on Orthomyxoviridae-Infektionen

Total 2030 results

Osivax
Hôpital Cochin; Clinact

Not yet recruiting

Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg

Influenza
The University of Hong Kong

Not yet recruiting

Influenza Vaccine With Topical Imiquimod in Influenza Vaccine Non-responsive Children

Influenza
Viriom

Not yet recruiting

Study Evaluating the Efficacy and Safety of AV5080 in Patients With Uncomplicated Influenza

Influenza

Russian Federation
University of Alabama at Birmingham

Recruiting

Functional Consequences of T-bet Expression in Flu-specific Memory B Cells After Live Attenuated Influenza Vaccine (LAIV) (LAIV)

Influenza, Human

United States
Seqirus

Active, not recruiting

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Quadrivalent Influenza Vaccine Compared to a Non-adjuvanted Quadrivalent Influenza Vaccine in Adults ≥65 Years of Age

Influenza, Human

Turkey, Belgium, Bulgaria, Czechia, Finland, Georgia, Italy, Korea, Republic of, Lithuania, Netherlands, Poland, Romania, Spain, Taiwan
Novartis Vaccines

Completed

Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects

Influenza

Finland, United States, Poland
Hoffmann-La Roche

Completed

Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households

Influenza

United States, China, Poland, Puerto Rico, Hungary, Turkey, Costa Rica, India, Japan, South Africa, Mexico, New Zealand, Israel, Bulgaria, Greece, Singapore, Spain, United Kingdom
Fatimah Dawood
Baylor College of Medicine; University of Utah; University of Arizona; Westat; Florida... and other collaborators

Terminated

Comparison of Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years

Influenza, Human

United States
Geisinger Clinic
National Institute on Aging (NIA); Massachusetts Institute of Technology; National...

Completed

High-risk Influenza Vaccine Alert

Influenza

United States
The Archer-Daniels-Midland Company
NEXT CRO

Completed

Study to Assess the Effect of Multistrain Probiotic on the Immune Response to the Influenza Vaccination (LUPIN)

Influenza

Greece
Pfizer

Completed

A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older

Influenza, Human

United States, Brazil, South Africa, Philippines, New Zealand, Chile, Argentina
Seqirus

Completed

Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age

Influenza, Human

United States
University of California, Los Angeles
National Institute of Allergy and Infectious Diseases (NIAID)

Active, not recruiting

Patient Portal Flu Vaccine Reminders (RCT 6)

Respiratory Tract Infections | Influenza

United States
University of California, Los Angeles
National Institute of Allergy and Infectious Diseases (NIAID); Los Angeles...

Completed

Patient Portal Flu Vaccine Reminders_RCT 5 (LADHS) (LADHS)

Respiratory Tract Infections | Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine

Influenza

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...

Completed

Response to Influenza Vaccine During Pregnancy (FLU-PG)

Influenza

United States
LiteVax BV
University Hospital, Ghent

Completed

Safety, Tolerability, and Immunogenicity of TETRALITE, a Novel Adjuvanted, Low-dose Influenza Vaccin (TETRALITE-I)

Influenza

Belgium
Shanghai Institute Of Biological Products

Completed

A Clinical Trial of A Quadrivalent Influenza Vaccine

Influenza

China
ModernaTX, Inc.

Completed

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults

Influenza

United States
St. Jude Children's Research Hospital

Completed

A Pilot Study of Influenza Viruses Isolated From Immunocompromised Children and Adolescents

Influenza, Human

United States
National Institute of Allergy and Infectious Diseases...

Completed

Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain

Influenza

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...

Withdrawn

Response to Inactivated Influenza Vaccine in Lymph Tissue and Blood (FLU-LN)

Influenza

United States
Vaxess Technologies
ICON plc; Q2 Solutions; Centricity Research

Completed

Phase 1 Evaluation of H1 Influenza Vaccine Delivered by MIMIX MAP

Influenza

Canada
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

Influenza, Human

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age

Influenza

China
Sanofi Pasteur, a Sanofi Company

Completed

Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively (GRC00097)

Influenza

United States
Pfizer

Completed

A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza

Influenza, Human

United States
British Columbia Centre for Disease Control
McGill University Health Centre/Research Institute of the McGill University... and other collaborators

Active, not recruiting

TITRE III: Influenza B Immunogenicity Investigation

Influenza

Canada
Medicago

Completed

Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older

Influenza

United States
Groupe Hospitalier Paris Saint Joseph

Completed

Evaluation of the Alere i Influenza A&B Nucleic Acid Amplification Versus Xpert Flu/RSV

Influenza

France
National Institute of Allergy and Infectious Diseases...

Completed

Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy Adults

Influenza

United States
Osivax
Novotech (Australia) Pty Limited; Harmony Clinical Research; Northern Beaches...

Completed

Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.

Influenza

Australia
Bill & Melinda Gates Medical Research Institute
Iqvia Pty Ltd

Withdrawn

Proof of Concept Trial of Adjuvant Activity of SWE, a Squalene-based -Oil-in-water Emulsion

Influenza
Jiangsu Province Centers for Disease Control and...
Changchun Institute of Biological Products Co., Ltd.

Completed

A Clinical Trial of an Quadrivalent Inactivated Influenza Vaccine in Healthy Children Aged 6 to 35 Months

Influenza

China
Seqirus

Completed

Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults

Influenza

Australia, New Zealand, Philippines, South Africa
Centers for Disease Control and Prevention
Kaiser Permanente; Baylor Scott and White Health; Abt Associates

Completed

Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP

Influenza

United States
Sanofi

Completed

Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) in Subjects Aged 3 Years Old and Above

Influenza

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Suspended

Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age (QHD00014)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine

Influenza

Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India

Influenza

India
Sanofi
Protein Sciences Corporation

Completed

Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)

Influenza

Philippines
Wake Forest University Health Sciences
Free Air

Completed

Evaluation of Free Air Portable Air Powered Respirator

Influenza

United States
Viriom

Completed

Dose Range Study to Evaluate the Efficacy and Safety of AV5080 in Patients With Influenza

Influenza

Russian Federation
KBio Inc

Completed

Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults

Influenza

United States
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T)

Influenza

United States
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older

Influenza

United States
University of Rochester

Completed

Influenza Immunity in Children

Influenza

United States
University of Pittsburgh

Completed

Clinical Characteristics and Outcomes in Patients Diagnosed With Novel Influenza A (H1N1)

Influenza

United States
Vaccitech (UK) Limited
Clinical Network Services (CNS) Pty Ltd

Terminated

Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults

Influenza

Australia

3

Subscribe